Daratumumab plus lenalidomide/bortezomib/dexamethasone in Black patients with transplant-eligible newly diagnosed multiple myeloma in GRIFFIN.

Authors

• Ajay K Nooka
• Jonathan L Kaufman
• Cesar Rodriguez
• Andrzej Jakubowiak
• Yvonne Efebera, OhioHealth
• Brandi Reeves
• Tanya Wildes
• Sarah A Holstein
• Larry D Anderson
• Ashraf Badros
• Leyla Shune
• Ajai Chari
• Huiling Pei
• Annelore Cortoos
• Sharmila Patel
• J Blake Bartlett
• Jessica Vermeulen
• Thomas S Lin
• Paul G Richardson
• Peter Voorhees

Document Type

Article

Publication Title

Blood cancer journal

First Page

63

Last Page

63

DOI

10.1038/s41408-022-00653-1

Publication Date

4-13-2022

Recommended Citation

Nooka AK, Kaufman JL, Rodriguez C, Jakubowiak A, Efebera Y, Reeves B, Wildes T, Holstein SA, Anderson LD Jr, Badros A, Shune L, Chari A, Pei H, Cortoos A, Patel S, Bartlett JB, Vermeulen J, Lin TS, Richardson PG, Voorhees P. Daratumumab plus lenalidomide/bortezomib/dexamethasone in Black patients with transplant-eligible newly diagnosed multiple myeloma in GRIFFIN. Blood Cancer J. 2022 Apr 13;12(4):63. doi: 10.1038/s41408-022-00653-1. PMID: 35418120; PMCID: PMC9007985.